Based on a strong rationale that B-cell lymphomas with CREBBP mutations are dependent on HDAC3 activity, HDAC3 inhibition has been recently demonstrated as a promising strategy for those mutant cases while wild-type tumors show modest responses [6, 11]. The gene discussed is HDAC3; the disease is B-cell non-Hodgkin lymphoma.